Skip to main content
Erschienen in: Current Oncology Reports 6/2021

01.06.2021 | Cardio-oncology (EH Yang, Section Editor)

Reaching Across the Aisle: Cardio-Oncology Advocacy and Program Building

verfasst von: Diego Sadler, Anita Arnold, Joerg Herrmann, Andres Daniele, Carolina Maria Pinto Domingues Carvalho Silva, Arjun K Ghosh, Sebastian Szmit, Roohi Ismail Khan, Luis Raez, Anne Blaes, Sherry-Ann Brown

Erschienen in: Current Oncology Reports | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This study aims to assess the current state of cardio-oncology in reference to advocacy efforts, access to care, and perspective of stakeholders in their ability to provide patient care as well as development of “across the aisle” synergy among cardiologists and oncologists and academic and non-academic centers in various worldwide locations.

Recent Findings

During the last decade, there has been a significant and diverse growth in cardio-oncology. We reviewed the experience from cardiologists and oncologists across different healthcare systems, the global trends, the role of collaborative networks, and the importance of advocacy efforts.

Summary

Cardio-oncology will continue to grow, but there is an unmet need to increase awareness, improve education, and expand access to care to larger segments of the cancer population in order to have a more significant impact on their health. The growing collaboration through professional societies and collaborative networks provides an opportunity to advance the cardiovascular care of cancer patients to meet the projected needs in a growing and more diverse population.
Literatur
1.
Zurück zum Zitat Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.CrossRef Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.CrossRef
2.
Zurück zum Zitat •• Herrmann J. From trends to transformation: where cardio-oncology is to make a difference. Eur Heart J. 2019;40:3898–900 This editorial highlights the increased cardiovascular disease mortality persistent for life in cancer patients and the role of cardio oncology particularly in those with better cancer prognosis (3).CrossRef •• Herrmann J. From trends to transformation: where cardio-oncology is to make a difference. Eur Heart J. 2019;40:3898–900 This editorial highlights the increased cardiovascular disease mortality persistent for life in cancer patients and the role of cardio oncology particularly in those with better cancer prognosis (3).CrossRef
3.
Zurück zum Zitat Sturgeon KN, Deng L, Bluethman SL, et al. A population based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40:3889–97.CrossRef Sturgeon KN, Deng L, Bluethman SL, et al. A population based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40:3889–97.CrossRef
4.
Zurück zum Zitat Bluethmann SM, Mariotto AB, Rowland JH. Anticipating the “Silver Tsunami”. Cancer Epidemiol Biomark Prev. 2016;25:1029–36.CrossRef Bluethmann SM, Mariotto AB, Rowland JH. Anticipating the “Silver Tsunami”. Cancer Epidemiol Biomark Prev. 2016;25:1029–36.CrossRef
5.
Zurück zum Zitat Fradley MG, Brown AC, Shields B, et al. Developing a comprehensive cardio-oncology program at a cancer institute: the Moffitt experience. Oncol Rev. 2017;11:340.PubMedPubMedCentral Fradley MG, Brown AC, Shields B, et al. Developing a comprehensive cardio-oncology program at a cancer institute: the Moffitt experience. Oncol Rev. 2017;11:340.PubMedPubMedCentral
6.
Zurück zum Zitat Barac A, Murtagh G, Douglas P, et al. Health of patients with cancer and cancer survivors. JACC. 2015;65:2739.CrossRef Barac A, Murtagh G, Douglas P, et al. Health of patients with cancer and cancer survivors. JACC. 2015;65:2739.CrossRef
7.
Zurück zum Zitat • Sadler D, Chaugalian C, Cubeddu R, Stone E, Samuel T, et al. Practical and cost effective model to build and sustain a cardio-oncology program. Cardio Oncol J. https://doi.org/10.1186/s40959-020-00063-xThis study describes how to set up and sustain a program utilizing existing institutional resources without additional investment. Describes the key 4 components for a program. • Sadler D, Chaugalian C, Cubeddu R, Stone E, Samuel T, et al. Practical and cost effective model to build and sustain a cardio-oncology program. Cardio Oncol J. https://​doi.​org/​10.​1186/​s40959-020-00063-xThis study describes how to set up and sustain a program utilizing existing institutional resources without additional investment. Describes the key 4 components for a program.
8.
Zurück zum Zitat •• Sadler D, Fradley M, Ismail Khan R, Raez L, Bhandare D, Elson L, et al. Florida Inter-Specialty Collaborative Project to improve cardio oncology awareness and identify existing gaps. JACC Cardio Onc. 2020;2(3):535–8 It describes the collaborative effort between cardiologists and oncologists and integration of the ACC and ASCO state chapters as a model to identify gaps in access to care in the community.CrossRef •• Sadler D, Fradley M, Ismail Khan R, Raez L, Bhandare D, Elson L, et al. Florida Inter-Specialty Collaborative Project to improve cardio oncology awareness and identify existing gaps. JACC Cardio Onc. 2020;2(3):535–8 It describes the collaborative effort between cardiologists and oncologists and integration of the ACC and ASCO state chapters as a model to identify gaps in access to care in the community.CrossRef
10.
Zurück zum Zitat • Sadler D, De Cara J, Herrmann J, Arnold A, Ghosh A, Abdel-Quadir H, et al. COVID-19 pandemic and its impact on cardio oncology: results from the COVID-19 International Collaborative Network Survey. Cardio Oncol. 2020. https://doi.org/10.21203/rs.3.rs-88776/v1This is the first collaborative project completed by the Cardio-Oncology Collaborative Network and a result of an international cooperation between cardiologists and oncologists. • Sadler D, De Cara J, Herrmann J, Arnold A, Ghosh A, Abdel-Quadir H, et al. COVID-19 pandemic and its impact on cardio oncology: results from the COVID-19 International Collaborative Network Survey. Cardio Oncol. 2020. https://​doi.​org/​10.​21203/​rs.​3.​rs-88776/​v1This is the first collaborative project completed by the Cardio-Oncology Collaborative Network and a result of an international cooperation between cardiologists and oncologists.
11.
Zurück zum Zitat Armenian S, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(8):893–1.CrossRef Armenian S, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(8):893–1.CrossRef
12.
Zurück zum Zitat • Blaes A, Konety S. Cardiovascular disease in breast cancer survivors: an important topic in breast cancer survivorship. JNCI. 2020. https://doi.org/10.1093/jnci/djaa097This editorial highlights the increased cardiovascular mortality among breast cancer survivors compared to cancer-free women, particularly in elderly patients and in those with estrogen receptor-positive status and reviews other cohorts and risk factors in this population. • Blaes A, Konety S. Cardiovascular disease in breast cancer survivors: an important topic in breast cancer survivorship. JNCI. 2020. https://​doi.​org/​10.​1093/​jnci/​djaa097This editorial highlights the increased cardiovascular mortality among breast cancer survivors compared to cancer-free women, particularly in elderly patients and in those with estrogen receptor-positive status and reviews other cohorts and risk factors in this population.
13.
Zurück zum Zitat Bradshaw PT, Stevens J, Khankari N, Teitelbaum SL, Neugut AI, Gammon MD. Cardiovascular disease mortality among breast cancer survivors. Epidemiology. 2016;27(1):6–13.CrossRef Bradshaw PT, Stevens J, Khankari N, Teitelbaum SL, Neugut AI, Gammon MD. Cardiovascular disease mortality among breast cancer survivors. Epidemiology. 2016;27(1):6–13.CrossRef
14.
Zurück zum Zitat Gilchrist S, Barac A, Ades P, et al. On behalf of the American Heart Association Exercise, Cardiac Rehabilitation and Secondary Prevention Committee. Circulation. 2019;139:e997–e1012.CrossRef Gilchrist S, Barac A, Ades P, et al. On behalf of the American Heart Association Exercise, Cardiac Rehabilitation and Secondary Prevention Committee. Circulation. 2019;139:e997–e1012.CrossRef
17.
Zurück zum Zitat • Ghosh AK, Manisty C, Woldman S, Crake T, Westwood M, Walker JM. Setting up cardio-oncology services. Br J Cardiol. 2017;24(1):1. https://doi.org/10.5837/bjc.2017.003In this article they describe the requirements for cardio-oncology services and reflect their experiences in setting up these services at large academic hospitals in London, UK.CrossRef • Ghosh AK, Manisty C, Woldman S, Crake T, Westwood M, Walker JM. Setting up cardio-oncology services. Br J Cardiol. 2017;24(1):1. https://​doi.​org/​10.​5837/​bjc.​2017.​003In this article they describe the requirements for cardio-oncology services and reflect their experiences in setting up these services at large academic hospitals in London, UK.CrossRef
21.
Zurück zum Zitat • Opolski G, Krzakowski M, Szmit S, Banach J, Chudzik M, Cygankiewicz I, et al. Recommendations of National Team of Cardiologic and Oncologic Supervision on cardiologic safety of patients with breast cancer. The prevention and treatment of cardiovascular complications in breast cancer. The Task Force of National Consultants in Cardiology and Clinical Oncology for the elaboration of recommendations of cardiologic proceeding with patients with breast cancer. Kardiol Pol. 2011;69(5):520–30 Describes the set-up, requirements, and guidelines for cardio-oncology clinics and programs in Poland.PubMed • Opolski G, Krzakowski M, Szmit S, Banach J, Chudzik M, Cygankiewicz I, et al. Recommendations of National Team of Cardiologic and Oncologic Supervision on cardiologic safety of patients with breast cancer. The prevention and treatment of cardiovascular complications in breast cancer. The Task Force of National Consultants in Cardiology and Clinical Oncology for the elaboration of recommendations of cardiologic proceeding with patients with breast cancer. Kardiol Pol. 2011;69(5):520–30 Describes the set-up, requirements, and guidelines for cardio-oncology clinics and programs in Poland.PubMed
22.
Zurück zum Zitat Zaborowska-Szmit M, Krzakowski M, Kowalski DM, Szmit S. Cardiovascular complications of systemic therapy in non-small-cell lung cancer. J Clin Med. 2020 Apr 27;9(5):1268.CrossRef Zaborowska-Szmit M, Krzakowski M, Kowalski DM, Szmit S. Cardiovascular complications of systemic therapy in non-small-cell lung cancer. J Clin Med. 2020 Apr 27;9(5):1268.CrossRef
23.
Zurück zum Zitat Szmit S, Grela-Wojewoda A, Talerczyk M, Kufel-Grabowska J, Streb J, Smok-Kalwat J, et al. Predictors of new-onset heart failure and overall survival in metastatic breast cancer patients treated with liposomal doxorubicin. Sci Rep. 2020 Oct 28;10(1):18481.CrossRef Szmit S, Grela-Wojewoda A, Talerczyk M, Kufel-Grabowska J, Streb J, Smok-Kalwat J, et al. Predictors of new-onset heart failure and overall survival in metastatic breast cancer patients treated with liposomal doxorubicin. Sci Rep. 2020 Oct 28;10(1):18481.CrossRef
24.
Zurück zum Zitat Styczkiewicz K, Styczkiewicz M, Mędrek S, Jankowski P, Szmit S, Stec S. Telecardio-onco AID: a new concept for a coordinated care program in breast cancer (BREAST-AID): rationale and study protocol. Pol Arch Intern Med. 2019;129(4):295–29.PubMed Styczkiewicz K, Styczkiewicz M, Mędrek S, Jankowski P, Szmit S, Stec S. Telecardio-onco AID: a new concept for a coordinated care program in breast cancer (BREAST-AID): rationale and study protocol. Pol Arch Intern Med. 2019;129(4):295–29.PubMed
25.
Zurück zum Zitat Jurczak W, Szmit S, Sobociński M, Machaczka M, Drozd-Sokołowska J, Joks M, et al. Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen - a national multicenter study. Int J Cardiol. 2013 Oct 15;168(6):5212–7.CrossRef Jurczak W, Szmit S, Sobociński M, Machaczka M, Drozd-Sokołowska J, Joks M, et al. Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen - a national multicenter study. Int J Cardiol. 2013 Oct 15;168(6):5212–7.CrossRef
26.
Zurück zum Zitat Szmit S, Jurczak W, Zaucha JM, Drozd-Sokołowska J, Spychałowicz W, Joks M, et al. Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma. J Am Soc Hypertens. 2014 Nov;8(11):791–9.CrossRef Szmit S, Jurczak W, Zaucha JM, Drozd-Sokołowska J, Spychałowicz W, Joks M, et al. Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma. J Am Soc Hypertens. 2014 Nov;8(11):791–9.CrossRef
27.
Zurück zum Zitat Szmit S, Jurczak W, Zaucha JM, Długosz-Danecka M, Sosnowska-Pasiarska B, Chmielowska E, et al. Acute decompensated heart failure as a reason of premature chemotherapy discontinuation may be independent of a lifetime doxorubicin dose in lymphoma patients with cardiovascular disorders. Int J Cardiol. 2017 May 15;235:147–53.CrossRef Szmit S, Jurczak W, Zaucha JM, Długosz-Danecka M, Sosnowska-Pasiarska B, Chmielowska E, et al. Acute decompensated heart failure as a reason of premature chemotherapy discontinuation may be independent of a lifetime doxorubicin dose in lymphoma patients with cardiovascular disorders. Int J Cardiol. 2017 May 15;235:147–53.CrossRef
28.
Zurück zum Zitat Długosz-Danecka M, Gruszka AM, Szmit S, Olszanecka A, Ogórka T, Sobociński M, et al. Primary cardioprotection reduces mrtality in lymphoma patients with increased risk of anthracycline cardiotoxicity, treated by R-CHOP regimen. Chemotherapy. 2018;63(4):238–45.CrossRef Długosz-Danecka M, Gruszka AM, Szmit S, Olszanecka A, Ogórka T, Sobociński M, et al. Primary cardioprotection reduces mrtality in lymphoma patients with increased risk of anthracycline cardiotoxicity, treated by R-CHOP regimen. Chemotherapy. 2018;63(4):238–45.CrossRef
29.
Zurück zum Zitat Jurczak W, Długosz-Danecka M, Szmit S. Cardio-oncology for better lymphoma therapy outcomes. Lancet Haematol. 2020 Apr;7(4):e273–5.CrossRef Jurczak W, Długosz-Danecka M, Szmit S. Cardio-oncology for better lymphoma therapy outcomes. Lancet Haematol. 2020 Apr;7(4):e273–5.CrossRef
30.
Zurück zum Zitat Zamorano JL, Lancellotti P, Muñoz DR, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Kardiol Pol. 2016;74(11):1193–233.CrossRef Zamorano JL, Lancellotti P, Muñoz DR, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Kardiol Pol. 2016;74(11):1193–233.CrossRef
34.
Zurück zum Zitat • Lenihan D, Carver J, Herrmann J, et al. Cardio-oncology care in the era of coronavirus disease 2019 (COVID-19) pandemic. An International Cardio-Oncology Society statement. CA Cancer J Clin. 2020;70(6):480–504 0:1-25. This is a very comprehensive document by ICOS identifying pathways for care of cardio-oncology patients according to their cardiovascular risk, cancer risk, and COVID-19 risk.CrossRef • Lenihan D, Carver J, Herrmann J, et al. Cardio-oncology care in the era of coronavirus disease 2019 (COVID-19) pandemic. An International Cardio-Oncology Society statement. CA Cancer J Clin. 2020;70(6):480–504 0:1-25. This is a very comprehensive document by ICOS identifying pathways for care of cardio-oncology patients according to their cardiovascular risk, cancer risk, and COVID-19 risk.CrossRef
35.
Zurück zum Zitat Sklar DP. Why effective healthcare advocacy is so important today. Acad Med. 2016;91:1325–8.CrossRef Sklar DP. Why effective healthcare advocacy is so important today. Acad Med. 2016;91:1325–8.CrossRef
Metadaten
Titel
Reaching Across the Aisle: Cardio-Oncology Advocacy and Program Building
verfasst von
Diego Sadler
Anita Arnold
Joerg Herrmann
Andres Daniele
Carolina Maria Pinto Domingues Carvalho Silva
Arjun K Ghosh
Sebastian Szmit
Roohi Ismail Khan
Luis Raez
Anne Blaes
Sherry-Ann Brown
Publikationsdatum
01.06.2021
Verlag
Springer US
Erschienen in
Current Oncology Reports / Ausgabe 6/2021
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-021-01059-1

Weitere Artikel der Ausgabe 6/2021

Current Oncology Reports 6/2021 Zur Ausgabe

Neuroendocrine Neoplasms (NS Reed, Section Editor)

Update on Histological Reporting Changes in Neuroendocrine Neoplasms

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.